These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 37314421)
21. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Cao H; Rao X; Jia J; Yan T; Li D Acta Diabetol; 2023 Mar; 60(3):325-335. PubMed ID: 36316605 [TBL] [Abstract][Full Text] [Related]
22. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis. Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519 [TBL] [Abstract][Full Text] [Related]
23. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242 [TBL] [Abstract][Full Text] [Related]
24. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664 [TBL] [Abstract][Full Text] [Related]
25. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905 [TBL] [Abstract][Full Text] [Related]
26. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Rigato M; Fadini GP; Avogaro A Diabetes Obes Metab; 2023 Oct; 25(10):2963-2969. PubMed ID: 37402697 [TBL] [Abstract][Full Text] [Related]
27. Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials. Miyashita S; Kuno T; Takagi H; Sugiyama T; Ando T; Valentin N; Shimada YJ; Kodaira M; Numasawa Y; Kanei Y; Bangalore S Diabetes Res Clin Pract; 2020 May; 163():108136. PubMed ID: 32272190 [TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Scheen AJ Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697 [TBL] [Abstract][Full Text] [Related]
29. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. Ruanpeng D; Ungprasert P; Sangtian J; Harindhanavudhi T Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28440590 [TBL] [Abstract][Full Text] [Related]
30. Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis. Zheng H; Liu M; Li S; Shi Q; Zhang S; Zhou Y; Su N Front Endocrinol (Lausanne); 2021; 12():706914. PubMed ID: 34484120 [TBL] [Abstract][Full Text] [Related]
31. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Tang HL; Li DD; Zhang JJ; Hsu YH; Wang TS; Zhai SD; Song YQ Diabetes Obes Metab; 2016 Dec; 18(12):1199-1206. PubMed ID: 27407013 [TBL] [Abstract][Full Text] [Related]
32. Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure : A Systematic Review and Meta-analysis. Zou X; Shi Q; Vandvik PO; Guyatt G; Lang CC; Parpia S; Wang S; Agarwal A; Zhou Y; Zhu Y; Tian H; Zhu Z; Li S Ann Intern Med; 2022 Jun; 175(6):851-861. PubMed ID: 35404670 [TBL] [Abstract][Full Text] [Related]
33. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Lega IC; Bronskill SE; Campitelli MA; Guan J; Stall NM; Lam K; McCarthy LM; Gruneir A; Rochon PA Diabetes Obes Metab; 2019 Nov; 21(11):2394-2404. PubMed ID: 31264755 [TBL] [Abstract][Full Text] [Related]
34. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821 [TBL] [Abstract][Full Text] [Related]
35. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Tsai WH; Chuang SM; Liu SC; Lee CC; Chien MN; Leung CH; Liu SJ; Shih HM Sci Rep; 2021 Jul; 11(1):15364. PubMed ID: 34321571 [TBL] [Abstract][Full Text] [Related]
36. Adverse Events of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review. Choi H; Nguyen LA; Wan J; Milani H; McGill K; Park J Perm J; 2021 May; 25():. PubMed ID: 33970086 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700 [TBL] [Abstract][Full Text] [Related]
38. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals. Lin DS; Lee JK; Chen WJ J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840 [TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials. Lee MC; Hua YM; Yang CT; Kuo FH; Chang WT; Tang HJ; Siong Toh H; Lin YM; Chen SY; Chang HY; Liao CT Medicine (Baltimore); 2022 Dec; 101(51):e32489. PubMed ID: 36595871 [TBL] [Abstract][Full Text] [Related]
40. Acute Renal Failure, Ketoacidosis, and Urogenital Tract Infections with SGLT2 Inhibitors: Signal Detection Using a Japanese Spontaneous Reporting Database. Katsuhara Y; Ogawa T Clin Drug Investig; 2020 Jul; 40(7):645-652. PubMed ID: 32451843 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]